Literature DB >> 9711881

Post-prandial serum hyaluronan concentration in patients with chronic liver disease.

Y Idobe1, Y Murawaki, Y Ikuta, M Koda, H Kawasaki.   

Abstract

Serum hyaluronan measurement is an option for diagnosing cirrhosis and assessing liver fibrosis, but it is of little use in the diagnosis of chronic hepatitis and compensated liver cirrhosis. It is generally known that intake of food results in elevation of the serum hyaluronan concentration. This work was designed to determine whether a change in the serum hyaluronan concentration after eating might reflect the hepatic sinusoidal endothelial cell impairment in chronic liver diseases. The chronological measurement of serum hyaluronan concentration after eating was performed after an overnight fast in 31 patients with chronic hepatitis, 31 cirrhotic patients, and 8 healthy subjects. The hyaluronan concentration in the loading test increased with the severity of the liver disease in the patients with chronic hepatitis, being significantly higher in the patients with moderate or a higher grade of necroinflammation than in those with a minimal grade, and also significantly higher in patients with stage 3 fibrosis than in those with stage 2 or less. The elevation of the concentration after eating in patients with liver cirrhosis was marked and the range did not overlap with that in patients with chronic hepatitis. Even in 14 patients with compensated liver cirrhosis whose hyaluronan concentration pre-prandially was less than 200 ng/ml, the range of the post-prandial peak concentration did not overlap with that in the chronic hepatitis patients. These results suggest that the evaluation of post-prandial serum hyaluronan concentration is potentially useful for assessing the grading of necroinflammation and staging of fibrosis in patients with chronic hepatitis, as well as for diagnosing compensated liver cirrhosis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9711881     DOI: 10.2169/internalmedicine.37.568

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  6 in total

1.  Clinical Utility of Biomarkers of Liver Fibrosis.

Authors:  Keyur Patel; Don C Rockey
Journal:  Gastroenterol Hepatol (N Y)       Date:  2006-01

2.  A quantitative index measured on ⁹⁹mTc GSA SPECT/CT 3D fused images to evaluate severe fibrosis in patients with chronic liver disease.

Authors:  Morikatsu Yoshida; Shinya Shiraishi; Fumi Sakaguchi; Daisuke Utsunomiya; Kuniyuki Tashiro; Seiji Tomiguchi; Hirohisa Okabe; Toru Beppu; Hideo Baba; Yasuyuki Yamashita
Journal:  Jpn J Radiol       Date:  2012-04-12       Impact factor: 2.374

3.  Hyaluronic acid levels predict increased risk of non-AIDS death in hepatitis-coinfected persons interrupting antiretroviral therapy in the SMART Study.

Authors:  Lars Peters; Jacqueline Neuhaus; Amanda Mocroft; Vincent Soriano; Jürgen Rockstroh; Gregory Dore; Massimo Puoti; Ellen Tedaldi; Bonaventura Clotet; Bernd Kupfer; Jens D Lundgren; Marina B Klein
Journal:  Antivir Ther       Date:  2011

Review 4.  A brief review on molecular, genetic and imaging techniques for HCV fibrosis evaluation.

Authors:  Waqar Ahmad; Bushra Ijaz; Sana Gull; Sultan Asad; Saba Khaliq; Shah Jahan; Muhammad T Sarwar; Humera Kausar; Aleena Sumrin; Imran Shahid; Sajida Hassan
Journal:  Virol J       Date:  2011-02-08       Impact factor: 4.099

Review 5.  Hyaluronic Acid: from biochemical characteristics to its clinical translation in assessment of liver fibrosis.

Authors:  Sahar Rostami; Hadi Parsian
Journal:  Hepat Mon       Date:  2013-12-14       Impact factor: 0.660

6.  Hyaluronic acid levels predict risk of hepatic encephalopathy and liver-related death in HIV/viral hepatitis coinfected patients.

Authors:  Lars Peters; Amanda Mocroft; Vincent Soriano; Jürgen Rockstroh; Andri Rauch; Anders Karlsson; Brygida Knysz; Christian Pradier; Kai Zilmer; Jens D Lundgren
Journal:  PLoS One       Date:  2013-05-27       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.